<DOC>
	<DOCNO>NCT02199223</DOCNO>
	<brief_summary>Evaluate safety regorafenib panitumumab</brief_summary>
	<brief_title>Regorafenib + Panitumumab Colorectal Cancers</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histological diagnosis unresectable metastatic colorectal cancer KRAS NRAS mutation negative ( wildtype ) . Patients know mutation KRAS NRAS codon 12 , 13 , 59 , 61 , 117 146 exclude . Mutations KRAS NRAS codon list allow . Biopsy metastatic lesion require . Patients must show sign progression ( image , tumor marker elevation ) treat first line great treatment unresectable metastatic colorectal cancer . Age 18 year old . ECOG Performance Status 01 Subjects must able understand willing sign write informed consent form . A sign informed consent form must appropriately obtain prior conduct trialspecific procedure . Acute toxic effect prior treatment resolve NCICTCAE v4.0 less equal Grade 1 baseline prior begin treatment . Alopecia ( grade ) allow . Peripheral neuropathy less equal Grade 2 allow . Adequate bone marrow , renal liver function assess protocol laboratory requirement Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug . Postmenopausal woman ( defined menses least 1 year ) surgically sterilize woman require undergo pregnancy test . Subjects ( men woman ) childbearing potential must agree use adequate contraception begin sign ICF least 3 month last dose study drug . Highly effective contraception must use ( e.g . male condom spermicidal , diaphragm spermicidal , intrauterine device ) must use sex . Subject must able swallow medication . Measurable disease screen RECIST 1.1 criterion Any known mutation KRAS NRAS codon 12 , 13 , 59 , 61 , 117 146 . Prior use regorafenib . Known suspect grade 3 allergy hypersensitivity study drug , study drug class , excipients formulation give course trial . Uncontrolled hypertension ( systolic pressure great than140 mm Hg diastolic pressure great 90 mm Hg [ NCICTCAE v4.0 ] mean 3 consecutive reading despite optimal medical management . Hypertension may correct add adjust antihypertensive prior initiation treatment discretion practitioner . Active clinically significant cardiac disease include congestive heart failure , uncontrolled cardiac arrhythmia , unstable angina . Evidence history congenital acquire hypocoagulability disorder . Any hemorrhage bleeding event great equal NCI CTCAE v.4.0 Grade 3 within 4 week prior start study medication . Subjects thrombotic , embolic , venous , arterial event , cerebrovascular accident ( include transient ischemic attack ) deep vein thrombosis pulmonary embolism initiate within 6 month start study treatment . Stable , persistent event appropriate management diagnose great 6 month prior treatment allow discretion investigator . Subjects receive treatment concurrent cancer distinct primary site histology colorectal carcinoma , except cancer insitu , treat basal cell squamous cell carcinoma , superficial bladder tumor . Subjects survive cancer curatively treat without evidence disease 1 year randomization allow . All cancer treatment must complete least 1 year prior start study treatment . Patients severe hepatic impairment ( ChildPugh Class C ) . Known history human immunodeficiency virus ( HIV ) infection current chronic active hepatitis B C infection require treatment antiviral therapy . Baseline testing require . Patients require IV antiviral IV antibiotic treatment ongoing infection . Symptomatic metastatic brain meningeal tumor . Baseline brain imaging require . Presence nonhealing wound bone fracture . Patient 's history kidney disease persistent proteinuria must less Grade 3 proteinuria per NCI CTCAE v4.0 screening . If patient history kidney disease persistent proteinuria , urine protein test perform random urine sample . If result normal additional testing require . If result abnormal , 24 hour urine collect determine proteinuria less Grade 3 . Interstitial lung disease ongoing sign symptoms time informed consent . Any malabsorption condition opinion investigator would significantly impact drug absorption . Women pregnant breastfeeding . Any condition , investigator 's opinion , make subject unsuitable trial participation . Substance abuse , medical , psychological social condition opinion investigator may interfere subject 's participation study evaluation study result . Concurrent anticancer therapy ( chemotherapy , radiation therapy , surgery , immunotherapy , biologic therapy , tumor embolization ) within 3 week start study treatment . Concurrent use another investigational drug device , within 3 week start study treatment . Major surgical procedure , open biopsy , significant traumatic injury within 3 week start study medication . Concurrent use strong CYP3a4 inducer ( e.g . rifampin , phenytoin , carbamazepine , phenobarbital , St. John 's Wort ) Concurrent use strong inhibitor CYP3A4 ( e.g . clarithromycin , grapefruit juice , itraconazole , ketoconazole , nefazadone , posaconazole , telithromycin , voriconazole )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>